Literature DB >> 8819580

Non-human primate models for AIDS vaccines.

R C Desrosiers1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8819580

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  19 in total

1.  Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells.

Authors:  P E Mangeot; D Nègre; B Dubois; A J Winter; P Leissner; M Mehtali; D Kaiserlian; F L Cosset; J L Darlix
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 2.  Nonhuman primate models in the genomic era: a paradigm shift.

Authors:  Eric J Vallender; Gregory M Miller
Journal:  ILAR J       Date:  2013

3.  Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.

Authors:  J Benson; C Chougnet; M Robert-Guroff; D Montefiori; P Markham; G Shearer; R C Gallo; M Cranage; E Paoletti; K Limbach; D Venzon; J Tartaglia; G Franchini
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 4.  A vaccine for HIV type 1: the antibody perspective.

Authors:  D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

5.  A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.

Authors:  J M Binley; R W Sanders; B Clas; N Schuelke; A Master; Y Guo; F Kajumo; D J Anselma; P J Maddon; W C Olson; J P Moore
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 6.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

7.  Simian-human immunodeficiency virus (SHIV) containing the nef/long terminal repeat region of the highly virulent SIVsmmPBj14 causes PBj-like activation of cultured resting peripheral blood mononuclear cells, but the chimera showed No increase in virulence.

Authors:  E B Stephens; S Mukherjee; Z Q Liu; D Sheffer; R Lamb-Wharton; K Leung; W Zhuge; S V Joag; Z Li; L Foresman; I Adany; O Narayan
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

8.  Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy.

Authors:  Edith Jasny; Suzanne Geer; Ines Frank; Panagiotis Vagenas; Meropi Aravantinou; Andres M Salazar; Jeffrey D Lifson; Michael Piatak; Agegnehu Gettie; James L Blanchard; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-01       Impact factor: 3.731

9.  Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.

Authors:  M S Wyand; K H Manson; M Garcia-Moll; D Montefiori; R C Desrosiers
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Simian immunodeficiency virus DNA vaccine trial in macaques.

Authors:  S Lu; J Arthos; D C Montefiori; Y Yasutomi; K Manson; F Mustafa; E Johnson; J C Santoro; J Wissink; J I Mullins; J R Haynes; N L Letvin; M Wyand; H L Robinson
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.